BMY Bristol-Myers Squibb Company Stock Quote

BMY [NYSE]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	-	EPS (ttm)	-2.27	Insider Own	0.10%	Shs Outstand	2.23B	Perf Week	-0.35%
Market Cap	152.82B	Forward P/E	8.49	EPS next Y	8.07	Insider Trans	-13.00%	Shs Float	2.20B	Perf Month	2.76%
Income	-5079.00M	PEG	-	EPS next Q	1.94	Inst Own	75.00%	Short Float	0.88%	Perf Quarter	5.89%
Sales	44.38B	P/S	3.44	EPS this Y	-298.80%	Inst Trans	0.20%	Short Ratio	2.08	Perf Half Y	10.41%
Book/sh	16.53	P/B	4.14	EPS next Y	7.85%	ROA	-4.30%	Target Price	75.37	Perf Year	15.17%
Cash/sh	6.28	P/C	10.90	EPS next 5Y	7.50%	ROE	-12.50%	52W Range	56.75 - 69.33	Perf YTD	10.41%
Dividend	1.96	P/FCF	20.53	EPS past 5Y	-44.40%	ROI	-12.10%	52W High	-1.21%	Beta	0.62
Dividend %	2.86%	Quick Ratio	1.40	Sales past 5Y	20.80%	Gross Margin	78.00%	52W Low	20.68%	ATR	0.99
Employees	30250	Current Ratio	1.50	Sales Q/Q	15.50%	Oper. Margin	-15.70%	RSI (14)	56.71	Volatility	1.53% 1.44%
Optionable	Yes	Debt/Eq	1.23	EPS Q/Q	-	Profit Margin	-11.40%	Rel Volume	0.63	Prev Close	69.31
Shortable	Yes	LT Debt/Eq	1.15	Earnings	Jul 28 BMO	Payout	-	Avg Volume	9.32M	Price	68.49
Recom	1.90	SMA20	1.29%	SMA50	2.62%	SMA200	7.63%	Volume	5,837,647	Change	-1.18%

Jul-27-21

Resumed

Truist

Buy

$74

Apr-30-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$70 → $62

Apr-13-21

Upgrade

Truist

Hold → Buy

Nov-16-20

Upgrade

Societe Generale

Hold → Buy

$76

Nov-10-20

Resumed

Bernstein

Mkt Perform

Nov-06-20

Downgrade

Gabelli & Co

Buy → Hold

Oct-19-20

Upgrade

Guggenheim

Neutral → Buy

$70

Sep-29-20

Initiated

Berenberg

Buy

$73

Jul-28-20

Initiated

Raymond James

Outperform

$75

Apr-02-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$64

Mar-23-20

Downgrade

Societe Generale

Buy → Hold

$50

Feb-27-20

Initiated

Barclays

Equal Weight

$69

Jan-06-20

Resumed

Citigroup

Buy

$73

Dec-13-19

Upgrade

Argus

Hold → Buy

$80

Nov-22-19

Resumed

Morgan Stanley

Equal-Weight

$60

Oct-17-19

Resumed

BofA/Merrill

Buy

$60

Aug-14-19

Upgrade

Atlantic Equities

Neutral → Overweight

$63

May-28-19

Initiated

Goldman

Buy

May-20-19

Downgrade

Argus

Buy → Hold

May-03-19

Upgrade

Barclays

Equal Weight → Overweight

$53 → $55

Aug-03-21 07:00AM	Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland Business Wire
Jul-31-21 10:50AM	12 Best Bear Market Stocks to Buy Now Insider Monkey
Jul-30-21 12:31PM	15 Most Valuable Biotech Companies in the World Insider Monkey
06:59AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy Business Wire
Jul-29-21 11:41AM	Why Compugen Stock Is Rising Again Today Motley Fool
Jul-28-21 04:15PM	Bristol Myers Retakes Buy Point After 'Solid' Quarter, Though Generics Loom Investor's Business Daily
03:14PM	Is BMY Stock A Buy After A Second-Quarter Beat As Revlimid Rivals Loom? Investor's Business Daily
01:57PM	Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow Zacks
12:00PM	Bristol-Myers Squibb (BMY) Q2 2021 Earnings Call Transcript Motley Fool
10:08AM	Bristol Myers Squibb Stock Rises After Modest Earnings Beat Barrons.com
08:15AM	Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates Zacks
07:42AM	Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance Benzinga
07:12AM	Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth MarketWatch
07:00AM	Bristol Myers sees return to growth for Opdivo, tops estimates Reuters
06:59AM	Bristol Myers Squibb Reports Second Quarter Financial Results for 2021 Business Wire
04:47AM	Bristol Myers Posts Stronger-Than-Expected Earnings but Lowers Guidance TheStreet.com
Jul-27-21 02:20PM	Top Analyst Reports for Comcast, Coca-Cola & Bristol-Myers Squibb Zacks
11:14AM	Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY Zacks
10:40AM	Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings Benzinga
06:00AM	Why Its Hard to Go Wrong With Bristol Myers Stock Barrons.com
Jul-26-21 02:29PM	Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings? Zacks
12:21PM	Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer Benzinga
06:06AM	3 Warren Buffett Stocks That Are Screaming Summer Buys Motley Fool
Jul-23-21 05:45PM	Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know Zacks
Jul-22-21 05:50PM	Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
11:10AM	Healthcare ETFs in Focus as Q2 Earnings Unfold Zacks
10:33AM	Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term Zacks
08:15AM	2 Dirt Cheap Dividend Stocks You Can Buy Right Now Motley Fool
05:51AM	7 Stocks to Buy Hand Over Fist if the Stock Market Crashes Motley Fool
Jul-21-21 03:02PM	Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy? Zacks
Jul-20-21 05:58AM	Got $5,000? Here Are 2 Cheap Warren Buffett Stocks to Buy Motley Fool
Jul-19-21 04:20PM	Will Small Biotech Stock Cytokinetics Undermine A Bristol Myers Buyout? Investor's Business Daily
11:32AM	Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study Zacks
06:00AM	Cytokinetics Soars on Positive Results of Heart Disease Treatment Test TheStreet.com
Jul-17-21 08:49AM	Have $1,000? 2 Warren Buffett Stocks to Buy Motley Fool
Jul-16-21 05:45PM	Bristol Myers Squibb (BMY) Stock Moves -0.19%: What You Should Know Zacks
12:46PM	10 Best Blue Chip Dividend Stocks Hedge Funds Are Buying Insider Monkey
08:05AM	Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial Benzinga
07:10AM	Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goals MarketWatch
06:59AM	Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck Business Wire
Jul-15-21 05:50PM	Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
06:38AM	XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences Benzinga
Jul-14-21 12:57PM	10 Best Psychedelic Stocks to Buy Now Insider Monkey
Jul-11-21 09:31AM	2 Biotech IPO Stocks You'll Want to Have on Your Radar Motley Fool
Jul-10-21 08:01AM	Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy? Motley Fool
Jul-09-21 05:45PM	Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know Zacks
01:22PM	Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H Zacks
Jul-08-21 05:50PM	Bristol Myers Squibb (BMY) Stock Moves -0.67%: What You Should Know Zacks
10:00AM	After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold Benzinga
Jul-06-21 09:20AM	Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments MarketWatch
05:55AM	3 Dividend Stocks That Are Dirt Cheap Right Now Motley Fool
Jul-02-21 05:45PM	Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know Zacks
Jul-01-21 05:50PM	Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
06:05AM	Could Vertex Pharmaceuticals Be a Prime Acquisition Target? Motley Fool
Jun-30-21 04:04PM	Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More Zacks
01:42PM	15 Best Medical Stocks to Invest In Insider Monkey
Jun-29-21 02:22PM	Is BMY Stock A Buy As Shares Surge On Promising Cancer Treatment Data? Investor's Business Daily
07:06AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite InstabilityHigh Metastatic Colorectal Cancer After Prior Chemotherapy Business Wire
Jun-28-21 04:25PM	Analyst Expects Bristol to Settle Over $6 Billion Bet That Didnt Pay Out Barrons.com
01:20PM	Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma Zacks
11:28AM	16 Best Beginner Stocks to Invest in Right Now Insider Monkey
Jun-26-21 06:06AM	5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021 Motley Fool
Jun-25-21 06:59AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy Business Wire
06:50AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma Business Wire
Jun-24-21 01:34AM	Update: Bristol-Myers Squibb (NYSE:BMY) Stock Gained 18% In The Last Three Years Simply Wall St.
Jun-21-21 05:05PM	Bristol Myers' (BMY) Onureg Gets European Commission Approval Zacks
Jun-18-21 02:09PM	Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate Zacks
09:34AM	Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia Business Wire
07:05AM	Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights Benzinga
Jun-17-21 07:17PM	UPDATE 1-Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate Reuters
06:47PM	Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate Reuters
06:30PM	Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisais MORAb-202 Antibody Drug Conjugate Business Wire
04:16PM	Bristol Myers Squibb Announces Dividend Business Wire
11:00AM	Supreme Court upholds Obamacare in latest ruling Yahoo Finance Video
Jun-15-21 11:39AM	Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers Zacks
Jun-14-21 02:47PM	Is Bristol Myers Squibb Company (BMY) Going to Burn These Hedge Funds? Insider Monkey
07:35AM	Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma Benzinga
05:51AM	Here's Where to Invest $1,000 Right Now Motley Fool
Jun-13-21 09:01AM	How Big Is Bristol Myers Squibb's Latest FDA Approval? Motley Fool
Jun-11-21 12:38PM	Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi Zacks
03:00AM	Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia Business Wire
Jun-10-21 04:16PM	Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience Business Wire
12:22PM	S&P 500 Rides Falling Yields to Record Highs as Bond Bears Cower Investing.com
09:50AM	Bristol-Myers Higher on Progress With Lymphoma-Drug Trial TheStreet.com
09:10AM	Bristol Up As New Therapys Phase-3 Trial In Lymphoma Is Positive Investing.com
07:05AM	Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021 Business Wire
06:59AM	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma Business Wire
Jun-09-21 06:06AM	3 Buffett Stocks to Buy Hand Over Fist in June Motley Fool
Jun-04-21 02:51PM	Top Stock Reports for Berkshire Hathaway, CocaCola & Oracle Zacks
08:14AM	Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution Benzinga
06:59AM	Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference Business Wire
Jun-03-21 05:01PM	Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Business Wire
03:16PM	Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters Benzinga
09:43AM	Bristol-Myers is sued for $6.4 billion over delayed cancer drug Reuters
09:37AM	Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug Reuters
08:22AM	Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma Zacks
Jun-02-21 08:00AM	Health Canada Approves OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma CNW Group
06:59AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma Business Wire
06:59AM	Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases Business Wire
01:44AM	15 Most Valuable Pharmaceutical Companies In The World Insider Monkey

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Powell Ann	EVP, Chief Human Resources	Aug 03	Sale	68.57	23,280	1,596,310	47,613	Aug 04 04:46 PM
Caforio Giovanni	Chairman and CEO	Aug 02	Sale	68.58	20,000	1,371,600	508,980	Aug 04 04:47 PM
Elkins David V	EVP, Chief Financial Officer	Aug 01	Option Exercise	0.00	46,403	0	133,435	Aug 03 04:55 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Jul 30	Option Exercise	58.49	150,967	8,830,108	187,617	Aug 03 04:50 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	Jul 30	Sale	67.90	2,466	167,441	13,777	Aug 03 04:56 PM
LEUNG SANDRA	EVP, General Counsel	Jul 30	Sale	68.04	29,390	1,999,696	339,967	Aug 03 04:54 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Jul 30	Sale	68.07	158,393	10,782,154	36,650	Aug 03 04:50 PM
von Autenried Paul	EVP, Chief Information Officer	Jul 30	Sale	68.06	25,000	1,701,375	114,670	Aug 03 04:49 PM
Santiago Karen Murphy	SVP & Controller	Jul 01	Option Exercise	0.00	1,069	0	15,045	Jul 06 04:38 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Jul 01	Option Exercise	0.00	9,356	0	16,538	Jul 06 04:38 PM
Haller Julia A	Director	Jun 13	Option Exercise	0.00	902	0	10,670	Jun 14 06:56 PM
BONNEY MICHAEL W	Director	Jun 13	Option Exercise	0.00	902	0	12,501	Jun 14 06:56 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Jun 03	Option Exercise	0.00	2,154	0	10,223	Jun 04 04:36 PM
Haller Julia A	Director	Jun 03	Option Exercise	0.00	2,949	0	9,768	Jun 04 04:35 PM
Schmukler Louis S	EVP,Pres.,Glob.Prod. & Supply	May 10	Sale	65.25	15,000	978,750	31,956	May 11 04:39 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	May 10	Sale	65.00	1,118	72,670	8,069	May 11 04:39 PM
VESSEY RUPERT	EVP, Research & Early Dev.	May 08	Option Exercise	0.00	17,245	0	62,384	May 11 04:38 PM
VESSEY RUPERT	EVP, Research & Early Dev.	May 05	Sale	64.29	30,546	1,963,802	45,139	May 07 04:56 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	May 05	Sale	64.21	3,119	200,271	16,243	May 07 04:57 PM
Mily Elizabeth	EVP, Strategy & BD	Apr 01	Option Exercise	0.00	6,346	0	5,380	Apr 02 01:14 PM
Caforio Giovanni	Chairman and CEO	Mar 22	Sale	62.20	25,000	1,555,000	528,980	Mar 24 04:41 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	Mar 10	Option Exercise	0.00	5,404	0	19,811	Mar 12 06:59 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Mar 10	Option Exercise	0.00	25,215	0	41,325	Mar 12 06:59 PM
Caforio Giovanni	Chairman and CEO	Mar 10	Option Exercise	0.00	200,709	0	603,187	Mar 12 06:59 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Mar 10	Option Exercise	0.00	6,134	0	9,862	Mar 12 06:58 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10	Option Exercise	0.00	8,025	0	91,211	Mar 12 06:57 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10	Option Exercise	0.00	4,189	0	9,082	Mar 12 06:56 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10	Option Exercise	0.00	50,373	0	383,564	Mar 12 06:52 PM
Santiago Karen Murphy	SVP & Controller	Mar 10	Option Exercise	0.00	7,483	0	14,717	Mar 12 06:50 PM
Powell Ann	EVP, Chief Human Resources	Mar 10	Option Exercise	0.00	29,835	0	76,125	Mar 12 06:51 PM
von Autenried Paul	EVP, Chief Information Officer	Mar 10	Option Exercise	0.00	20,302	0	143,800	Mar 12 06:50 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 10	Option Exercise	0.00	7,423	0	79,051	Mar 12 06:50 PM
Schmukler Louis S	EVP,Pres.,Glob.Prod. & Supply	Mar 10	Option Exercise	0.00	31,575	0	53,018	Mar 12 06:50 PM
Elkins David V	EVP, Chief Financial Officer	Mar 01	Option Exercise	0.00	24,579	0	91,759	Mar 03 05:27 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 01	Option Exercise	0.00	23,349	0	80,572	Mar 03 05:26 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Feb 04	Option Exercise	0.00	3,592	0	58,409	Feb 08 07:28 PM
Elkins David V	EVP, Chief Financial Officer	Dec 31	Option Exercise	0.00	20,624	0	79,111	Jan 05 08:13 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Dec 31	Option Exercise	0.00	25,866	0	68,074	Jan 05 08:14 PM
AHMED NADIM	EVP and President, Hematology	Dec 31	Option Exercise	0.00	14,946	0	46,549	Jan 05 08:13 PM
Elkins David V	EVP, Chief Financial Officer	Dec 02	Option Exercise	0.00	8,792	0	63,574	Dec 03 08:24 PM
AHMED NADIM	EVP and President, Hematology	Dec 02	Option Exercise	0.00	6,594	0	34,983	Dec 03 08:24 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Dec 02	Option Exercise	0.00	8,792	0	46,714	Dec 03 08:24 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Dec 02	Option Exercise	0.00	2,637	0	23,670	Dec 03 08:23 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Dec 01	Option Exercise	0.00	2,825	0	5,359	Dec 03 05:15 PM
von Autenried Paul	EVP, Chief Information Officer	Nov 25	Sale	63.50	3	190	126,698	Nov 30 05:52 PM
von Autenried Paul	EVP, Chief Information Officer	Nov 24	Sale	62.75	20,000	1,255,000	126,701	Nov 25 04:31 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	Nov 24	Sale	63.39	900	57,051	15,186	Nov 25 04:32 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 23	Sale	61.34	13,421	823,244	37,922	Nov 25 04:32 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 19	Option Exercise	49.28	52,213	2,572,887	98,355	Nov 23 05:40 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 19	Sale	61.30	57,591	3,530,269	46,142	Nov 23 05:40 PM
AHMED NADIM	EVP and President, Hematology	Oct 30	Option Exercise	0.00	4,650	0	30,680	Nov 03 04:28 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Oct 30	Option Exercise	0.00	5,804	0	59,580	Nov 03 04:27 PM
Santiago Karen Murphy	SVP & Controller	Sep 01	Option Exercise	0.00	642	0	8,390	Sep 02 04:33 PM
Caforio Giovanni	Chairman and CEO	Aug 31	Sale	62.70	39,840	2,497,968	445,584	Sep 02 04:34 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Aug 17	Sale	64.00	5,327	340,928	2,534	Aug 19 06:15 PM
LEUNG SANDRA	EVP, General Counsel	Aug 13	Sale	63.24	141,420	8,943,401	432,744	Aug 17 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience